Deanna Hunt, KBI Biopharma

Our panel concludes by looking ahead to the next-generation tools and techniques shaping bioconjugate characterization.

The FDA’s 2026 draft guidance shifts more responsibility onto analytical characterization for product safety.

As bioconjugate drug manufacturing moves to scale, certain critical quality attributes (CQAs) are hardest to control.

Two analytical experts explain how they use orthogonal methods to characterize bioconjugates without creating workflow bottlenecks.

Biophysical techniques can be used to catch bioconjugate aggregation and stability issues to prevent delays in drug development.

Understand why a best-in-class antibody drug conjugate (ADC) depends on balancing antibody, linker, conjugation chemistry, and payload together.

Specific critical quality attributes (CQAs) matter most when designing an antibody drug conjugate (ADC) program for long-term success.

New conjugation chemistries and peptide-based linkers improve linker stability in antibody-drug conjugates (ADCs).

Experts trace how the bioconjugate field has transformed since 2016 and where it is headed next.

Bioconjugate analytical experts set up for a discussion on next-generation antibody drug conjugate (ADC) characterization.

Meet the moderator for this Peer Exchange on Next-Gen Bioconjugation: Designing-in Analytical Precision and Efficiency.